Navigation Links
The Parkinson's Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinson's Disease
Date:10/10/2007

NEW YORK, Oct. 10 /PRNewswire-USNewswire/ -- To mark 50 years of service to the Parkinson's community, the Parkinson's Disease Foundation (PDF) will present an authoritative round-up of the state of Parkinson's research at a two-day symposium on Thursday, October 11 and Friday, October 12. The jam-packed program will feature 43 top-notch Parkinson's professionals presenting the latest news in Parkinson's science and quality of life initiatives.

The meeting, entitled Frontiers of Science and Clinical Advances in Quality of Life, will be open to everyone touched by Parkinson's disease including researchers, clinicians, allied health professionals, people with Parkinson's and caregivers. It is being jointly sponsored by PDF and The Movement Disorders Society and will be held in the historic South Street Seaport district of lower Manhattan.

The Scientific Program Committee, led by PDF's Scientific Director, Stanley Fahn, M.D., the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University, will cover a wide range of topics including epidemiology, biomarkers for PD, neuroprotection and gene therapy. "This is going to be a comprehensive review of where we have been and where we are going in Parkinson's research, presented by premier neuroscientists in the field," said Dr. Fahn.

The Clinical Advances in Quality of Life Program Committee is led by Lucien Cte, M.D., Professor of Neurology at Columbia University, and Karen Marder, M.D., M.P.H., the Sally Kerlin Professor of Neurology at Columbia University. "With a disease like Parkinson's, where everyone's case is unique, it is crucial to realize how it affects day-to-day living. These are the issues that we are going to focus on, the issues that can make a real difference in the way a person lives," said Dr. Cte. Specifically, sessions will focus on the preclinical diagnosis of Parkinson's disease; respiratory, gastrointestinal, urological and sexual issues; sleep disorders; caregiver support and the therapeutic effect of exercise.

A high point of the event will be the presentation, at a celebratory dinner following the first day's program, of the James Parkinson Award, PDF's highest honor, which is given only once each decade. This year, the award will go to Dr. Stanley Fahn, in recognition of his lifetime of achievement as a scientist and clinician in Parkinson's disease.

At the same reception, PDF will present a special 50th Anniversary Award for Exemplary Contributions to the Advancement of Parkinson's Science. The award will go jointly to Dr. Alim-Louis Benabid, Chairman of Neurosurgery at Joseph Fourier University in Grenoble, France, and Dr. Mahlon DeLong, Professor of Neurology at Emory University, for their pioneering work in developing deep brain stimulation (DBS) for Parkinson's disease.

PDF will also be recognizing Rhona Johnson with the very first Award for Leadership in Caregiving, an honor that will be presented by Lonnie Ali, wife and caregiver of Muhammad Ali. Ms. Johnson became involved with the Parkinson's community through the diagnosis of her now late husband Bob, in 1994, to whom she was sole caregiver.

Seats for the symposium are sold out; however, those who are not able to attend the event may view the symposium for free via webcast by visiting http://www.pdf.org/50th.

The symposium is made possible by our generous supporters: Boehringer Ingelheim Pharmaceuticals, Inc.; HealthShares, Inc.; Novartis Pharmaceuticals; UCB, Inc.; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Carol and Melvin Taub and Family; Valeant Pharmaceuticals North America; The Avicena Group; IMPAX Pharmaceuticals, Inc.; Medtronic, Inc.; the Medtronic Foundation; PatientsLikeMe, Inc.; Sepracor; Solstice Neurosciences, Inc.; Teva Neuroscience; Vernalis Pharmaceuticals, Inc.; Biogen Idec; Ceregene, Inc.; GE Healthcare Financial Services; Kyowa Pharmaceutical, Inc.; and ParkinsonsCommunity.org.

About the Parkinson's Disease Foundation

The Parkinson's Disease Foundation (PDF) is a leading national presence in Parkinson's disease research, education and public advocacy. We are working for the nearly one million people in the US living with Parkinson's by funding promising scientific research and supporting people with Parkinson's, their families and caregivers through education programs and support services. Since our founding in 1957, PDF has funded over $70 million worth of scientific research in Parkinson's disease, supporting the work of leading scientists throughout the world.


'/>"/>
SOURCE Parkinson's Disease Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New PCR Primers for Human Diseases
2. Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System
3. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
4. Th1 and Th2 Balance, Regulation, and Involvement in Disease
5. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
6. Medical College receives $377K to study brain disease
7. Thompsons HHS legacy will include efforts to combat disease in Africa
8. Stem cells produce anti-disease protein in brain experiment
9. Neurognostics pushes early prediction of brain disease
10. ZyStor receives first funding and buys theraputics for rare diseases
11. Predictive medicine: Genes indicate diseases before symptoms do
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
Breaking Biology News(10 mins):